Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

The company's strong cash position gives investors confidence in the gene-editing stock.

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

Scientists from Vilnius University's (VU) Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This research, led by Prof. Patrick Pausch ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

“It’s something we need to pay attention to, especially as CRISPR expands to more diseases,” Sam Kulkarni, the CEO of CRISPR Therapeutics, which was not involved with either study, tells STAT News.

Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...